The NAVIGATE-PF trial evaluates the Farawave Nav Pulsed Field Ablation (PFA) Catheter visualized & tracked by the Faraview Software Module in paroxysmal or persistent AF patients (n=~30). The US FDA’s approval is anticipated in H2’24
In the study, all participants will undergo cardiac mapping while pulmonary vein isolation will be carried out in paroxysmal AF & additional posterior wall isolation will be performed in persistent AF patients
The Farawave Nav PFA Catheter introduces magnetic navigation abilities to the Farawave PFA catheter, facilitating detailed mapping & PFA therapy in one device. The Faraview Software Module will visualize mapping data, providing a solution for procedures using the Farapulse PFA System
Ref: Boston Scientific | Image: Boston Scientific
Related News:- The US FDA Grants Approval to Boston Scientific’s Farapulse Pulsed Field Ablation (PFA) System for Atrial Fibrillation (AF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
